• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Estimating COVID-19 incidence and prevalence using lateral flow tests in England and Scotland, 2023-2024

tetano

Editor, Senior Moderator
Nat Commun


. 2026 Jan 16.
doi: 10.1038/s41467-025-67272-9. Online ahead of print.
Estimating COVID-19 incidence and prevalence using lateral flow tests in England and Scotland, 2023-2024

Martyn Fyles[SUP] 1 [/SUP], Jonathon Mellor[SUP] 2 [/SUP], Robert S Paton[SUP] 2 [/SUP], Christopher E Overton[SUP] 2 3 [/SUP], Alexander M Phillips[SUP] 2 4 [/SUP], Alex Glaser[SUP] 2 [/SUP], Thomas Ward[SUP] 2 [/SUP]


Affiliations
Free article Abstract

SARS-CoV-2 continues to cause substantial morbidity and mortality, particularly in winter. During the SARS-CoV-2 pandemic, community prevalence surveys provided detailed monitoring of infection levels. The Winter Coronavirus (COVID-19) Infection Survey (WCIS), conducted in England and Scotland from the 14[SUP]th[/SUP] November 2023 to the 7[SUP]th[/SUP] March 2024, enabled the UK Health Security Agency to publish fortnightly estimates of community infection levels in England and Scotland. Unlike previous community prevalence surveys, WCIS conducted testing using Lateral Flow Device (LFD) tests, and featured a repeat testing design that enabled estimation of key epidemiological parameters. LFD tests have a substantially lower cost per unit than Polymerase Chain Reaction (PCR) tests which were used in previous SARS-CoV-2 prevalence surveys; however, they have a high false negative rate that must be accounted for to produce reliable estimates. In this manuscript, statistical methods to robustly estimate incidence and prevalence while adjusting for time-varying false negative rates are developed. This enabled timely and robust inference of the incidence and prevalence of SARS-CoV-2, stratified by age group, location and sex. Overall, the study design of WCIS overcame key limitations of earlier large-scale community prevalence studies and demonstrated the utility of LFD tests in infectious disease surveillance.


 
Back
Top Bottom